Adgre2 chimeric receptor nk cell compositions and methods of use
AssigneeTakeda Pharmaceutical Company Limited
InventorsJames Gavin, Michael Curley, Lan Cao
Life of this patent
Estimating the term…
Abstract
The present application provides cord blood-derived natural killer (CB-NK) cells engineered to express chimeric receptors that target ADGRE2. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
Claims31
A cord blood natural killer (CB-NK) cell, comprising a chimeric receptor comprising an extracellular antigen-binding domain that binds to ADGRE2, a transmembrane domain, and an intracellular domain, wherein the extracellular antigen-binding domain comprises
- a heavy chain variable region comprises a HCDR1 comprising an amino acid sequence of GYTFTNYW (SEQ ID NO:
- 1), a HCDR2 comprising an amino acid sequence of VYPGDGDT (SEQ ID NO:
- 2) and a HCDR3 comprising an amino acid sequence of ARGFTAYGMDY (SEQ ID NO:
- 3);
- and
- a light chain variable region comprises a LCDR1 comprising an amino acid sequence of SSVSY (SEQ ID NO:
- 4), a LCDR2 comprising an amino acid sequence of DTS (SEQ ID NO:
- 5), and a LCDR3 comprising an amino acid sequence of QQWSSNPLT (SEQ ID NO:
- 6).
4-6. (canceled)
(canceled)
13-14. (canceled)
16-27. (canceled)
29-30. (canceled)
(canceled)
34-37. (canceled)
40-42. (canceled)
(canceled)
(canceled)
49-57. (canceled)
A cord blood natural killer (CB-NK) cell comprising a nucleic acid encoding a chimeric receptor and an exogenous IL-15 polypeptide, wherein the chimeric receptor comprises
- an extracellular antigen-binding domain that binds to ADGRE2 comprising a heavy chain variable region comprises a HCDR1 comprising an amino acid sequence of GYTFTNYW (SEQ ID NO:
- 1), a HCDR2 comprising an amino acid sequence of VYPGDGDT (SEQ ID NO:
- 2) and a HCDR3 comprising an amino acid sequence of ARGFTAYGMDY (SEQ ID NO:
- 3);
- and a light chain variable region comprises a LCDR1 comprising an amino acid sequence of SSVSY (SEQ ID NO:
- 4), a LCDR2 comprising an amino acid sequence of DTS (SEQ ID NO:
- 5), and a LCDR3 comprising an amino acid sequence of QQWSSNPLT (SEQ ID NO:
- 6).
A nucleic acid encoding a chimeric receptor and an exogenous IL-15 polypeptide, wherein the chimeric receptor comprises
- an extracellular antigen-binding domain that binds to ADGRE2 comprising a heavy chain variable region comprises a HCDR1 comprising an amino acid sequence of GYTFTNYW (SEQ ID NO:
- 1), a HCDR2 comprising an amino acid sequence of VYPGDGDT (SEQ ID NO:
- 2) and a HCDR3 comprising an amino acid sequence of ARGFTAYGMDY (SEQ ID NO:
- 3);
- and
- a light chain variable region comprises a LCDR1 comprising an amino acid sequence of SSVSY (SEQ ID NO:
- 4), a LCDR2 comprising an amino acid sequence of DTS (SEQ ID NO:
- 5), and a LCDR3 comprising an amino acid sequence of QQWSSNPLT (SEQ ID NO:
- 6).
Dependencies are inferred from the claim text.